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Abstract
Amaç: Bu çalışmada, kemik iliğindeki (Kİ) blast oranı >%30 olan olguları 
da içeren akut miyeloid lösemili (AML) yaşlı hastalarda, azasitidinin 
(AZA) etkinliğinin ve güvenliğinin araştırılmasını amaçladık.
Gereç ve Yöntemler: Bu geriye dönük, çok merkezli çalışmaya, 
yoğun kemoterapi için uygun olmayan ya da konvansiyonel tedavilere 
rağmen hastalığı ilerleyen ≥60 yaştaki 130 hasta dahil edildi.
Bulgular: Ortanca yaş 73 idi, hastaların %61,5’inde Kİ blast oranı 
>%30 olarak bulundu. Hastalar, ortanca 4 döngü (1-21 aralığında) 
AZA almıştı. Başlangıç genel yanıt oranı [tam yanıtı (TY)/eksik 
düzelmenin olduğu TY/kısmi yanıtı içeren] %36,2 idi. Herhangi bir 
hematolojik düzelme (HD), tüm hastaların %36,2’sinde tespit edildi. 
HD tedaviye yanıtsız hastaların %27,1’inde de saptandı. Ortanca 
genel sağkalım, yanıt verenlerde 18 ay, yanıt vermeyenlerde 12 ay idi 
(p=0,005). Tedaviye yanıtsız hasta grubunda HD’nin, HD olmayanlara 
kıyasla genel sağkalımı arttırdığı görüldü (ortanca sağkalım 14 aya 
Objective: In this study, we aimed to investigate the efficacy and 
safety of azacitidine (AZA) in elderly patients with acute myeloid 
leukemia (AML), including patients with >30% bone marrow (BM) 
blasts. 
Materials and Methods: In this retrospective multicenter study, 
130 patients of ≥60 years old who were ineligible for intensive 
chemotherapy or had progressed despite conventional treatment were 
included. 
Results: The median age was 73 years and 61.5% of patients had 
>30% BM blasts. Patients received AZA for a median of four cycles 
(range: 1-21). Initial overall response [including complete remission 
(CR)/CR with incomplete recovery/partial remission] was 36.2%. 
Hematologic improvement (HI) of any kind was documented in 37.7% 
of all patients. HI was also documented in 27.1% of patients who 
were unresponsive to treatment. Median overall survival (OS) was 18 
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Introduction
Acute myeloid leukemia (AML) is predominantly a disease of 
older patients with a median age at diagnosis of ~70 years 
[1,2]. Older patients with AML have significant comorbidities, 
a poorer performance status, more unfavorable cytogenetic 
abnormalities, and a higher incidence of secondary AML than 
their younger counterparts and only approximately 1/3 of 
elderly AML patients are eligible for conventional anthracycline/
cytarabine-based intensive chemotherapeutic approaches 
[3,4,5]. However, overall results of intensive chemotherapy 
remain poor even for those who do meet inclusion criteria for 
such treatment [1,3,4,5]. Patients not suitable for intensive 
chemotherapy or who did not respond to these treatment 
options are frequently offered best supportive care (BSC) only, 
and the prognosis is dismal [6,7]. 
The hypomethylating agents decitabine and azacitidine (AZA) 
have significant activity in patients with a myelodysplastic 
syndrome (MDS) [8,9]. The use of AZA was associated with 
improved survival when compared to BSC or low-dose cytarabine 
in patients with high-risk MDS, including those with marrow 
blast counts ranging from 20% to 30%, leading to AZA approval 
in these disease categories [8,10]. In untreated or relapsed/
refractory AML, a few studies have also shown significant 
response rates of AZA therapy [11,12,13,14,15]. However, there 
are limited data showing the efficacy of AZA in AML patients 
with >30% bone marrow (BM) blasts.
In this retrospective multicenter study, we aimed to investigate 
the efficacy and safety of AZA in elderly patients with AML 
(including patients with >30% BM blasts) defined according to 
the World Health Organization (WHO). 
Materials and Methods
Patients and Eligibility Criteria
Between June 2009 and June 2014, 130 patients of ≥60 years old 
with AML from 16 specialized centers for hematology in Turkey, 
defined according to WHO criteria, were included. Eligibility 
criteria included all ≥60-year-old AML patients who were treated 
with at least one dose of AZA. Demographic data, comorbidities 
(cardiovascular diseases, diabetes mellitus, prior/concomitant 
malignancies, pulmonary disease, renal insufficiency), Eastern 
Cooperative Oncology Group (ECOG) status, transfusion 
dependency, cytogenetic risk status according to the refined 
Medical Research Council (MRC) criteria [16], treatment prior 
to AZA, and concomitant treatments were recorded. AZA was 
administered at 75 mg/m2 subcutaneously daily for 7 days and 
100 mg/m2 subcutaneously daily for 7 days. The local ethics 
committee approved this retrospective analysis. 
Efficacy and Safety Assessments
Assessment of response was performed after a median of 4 
cycles of AZA. BM aspirations/punctures were performed and 
reviewed by the principal investigator (hematologist) at each 
center. Overall responses including complete remission (CR), 
partial remission (PR), CR with incomplete recovery (CRi), and 
failure were defined according to International Working Group 
(IWG) criteria for AML [17]. Patients with persisting peripheral 
blasts following AZA were also classified as nonresponders if BM 
puncture was not performed. Hematologic improvement (HI) 
was evaluated using IWG criteria for MDS from the collected 
transfusion records of the patients [18]. Specific hematologic 
and nonhematological adverse events were graded according to 
Common Terminology Criteria for Adverse Events (CTCAE) v4.0, 
published on 28 May 2009, by the National Cancer Institute. 
All data including response, HI, and adverse events were 
determined and recorded by principal hematologists at the 
respective centers. 
Statistical Analysis
Categorical data were analyzed by chi-square or Fisher’s exact 
test according to expected count rule and summarized as 
frequency and percentage. Both univariate and multivariate 
logistic regression analyses were used to obtain the odds ratio 
(OR) of variables that significantly affected response rate. 
Survival times and curves were estimated by Kaplan-Meier 
method and compared by log-rank test. Both univariate and 
multivariate Cox regression models were constructed for 
obtaining the hazard ratio (HR) of variables that significantly 
kıyasla 10 ay, p=0,068). Doğu Kooperatif Onkoloji Grubu performans 
durumunun <2 olması, AZA döngü sayısının artması (≥5 döngü) ve 
herhangi bir HD olması, daha iyi genel sağkalımı öngörüyordu. Yaşın, 
AML tipinin, Kİ blast yüzdesinin etkisi yoktu. 
Sonuç: AZA, yaşlı, eşlik eden hastalıkları olan AML’li hastalarda, Kİ 
blast sayısından bağımsız olarak etkindir ve iyi tolere edilmektedir ve 
HD’nin, AZA ile tedaviye devam etmek için yeterli bir yanıt olduğu göz 
önünde bulundurulmalıdır.
Anahtar Sözcükler: Azasitidin, Akut miyeloid lösemi, Yaşlı, Kemik iliği 
blastları, Prognostik faktörler, Genel sağkalım
months for responders and 12 months for nonresponders (p=0.005). 
In the unresponsive patient group, any HI improved OS compared to 
patients without any HI (median OS was 14 months versus 10 months, 
p=0.068). Eastern Cooperative Oncology Group performance status of 
<2, increasing number of AZA cycles (≥5 courses), and any HI predicted 
better OS. Age, AML type, and BM blast percentage had no impact. 
Conclusion: We conclude that AZA is effective and well tolerated in 
elderly comorbid AML patients, irrespective of BM blast count, and 
HI should be considered a sufficient response to continue treatment 
with AZA.
Keywords: Azacitidine, Acute myeloid leukemia, Elderly, Bone marrow 
blasts, Prognostic factors, Overall survival 
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affected survival. Statistical analyses were performed with 
PASW v.18 software (Predictive Analytics Software is a registered 
trademark of SPSS Inc.), and p<0.05 was considered statistically 
significant.
Results
Patient Characteristics
Patient baseline characteristics are summarized in Table 1. A total 
of 130 patients with AML (58 women, 72 men) receiving AZA 
were included in the study. Median age was 73, ranging from 
60 to 88 years; 31.5% (n=41) of patients were 60-69 years old, 
49.2% (n=64) were 70-79 years old, and 19.2% (n=25) were ≥80 
years old. ECOG performance status (ECOG-PS) was ≥2 in 54.6% 
(n=71) and there were comorbidities in 66.2% (n=86) of the 
cases; of these, 89.5% (n=77) had <3 and 10.5% (n=9) had ≥3 
comorbidities. Lactate dehydrogenase (LDH) level was <225 IU/L in 
20.8% (n=27) and was ≥225 IU/L in 75.4% (n=98) of the cases, and 
40.8% (n=53) of the patients had a leukocyte count of >10x109/L. 
Median absolute neutrophil count (ANC) was 1.1x109/L, median 
hemoglobin concentration was 8.7 g/L, and median platelet 
count was 57x109/L. Ninety-four (72.3%) patients had peripheral 
blood blasts and 80 patients (61.5%) had >30% BM blasts. One 
hundred and twelve patients (86.2%) required erythrocyte and/
or thrombocyte transfusion (transfusion-dependent), while 5.4% 
had an unfavorable karyotype and 50.8% had an intermediate 
karyotype according to MRC criteria [16]. 
Treatment Modalities
While 54.6% (n=71) of the patients did not receive any treatment 
prior to AZA, intensive chemotherapy, hydroxyurea, low-dose 
cytarabine, erythropoietin-stimulating agents, iron chelation 
therapy, lenalidomide, and granulocyte-colony stimulating 
factor (G-CSF) were used in 16.9% (n=22), 16.9% (n=22), 5.4% 
(n=7), 3.1% (n=4), 1.5% (n=2), 0.8% (n=1), and 0.8% (n=1) of 
the cases, respectively. 
AZA was administered as first-line therapy in 79.2% of patients 
(n=103). No CR or early relapse after conventional (intensive) 
chemotherapy and after other disease-modifying treatments 
was the reason for AZA treatment in 13.8% (n=18) and 
6.9% (n=9) of patients, respectively. AZA was administered 
at 75 mg/m2 subcutaneously daily for 7 days and 100 mg/m2 
subcutaneously daily for 7 days in 81.5% and 18.5% of the 
patients, respectively. A median number of 4 (range: 1-21) 
AZA courses were given in 28-day intervals. In all AZA cycles, 
hydroxyurea (11.5%) or G-CSF (7.7%) was given concomitantly 
when deemed necessary by the treating physician.
Response to Azacitidine and Survival
Initial overall response (including CR/CRi/PR according to IWG) 
was evaluated after a median of 4 cycles of AZA. While there 
was no response in 53.8% (n=70) of patients, CR, CRi, and PR 
Table 1. Baseline characteristics.
Total number of patients, n 130
Median age, years (range) 73 (60-88)
Age categories, n (%)    
 60-69 years 41 (31.5)
 70-79 years 64 (49.2)
 ≥80 years 25 (19.2)
Males, n (%) 72 (55.4)
Type of AML, n (%)  
 t-AML 6 (4.6)
 AML-RCA                9 (6.9)
 AML-MRF 47 (36.2)
 AML-NOS  68 (52.3)
Peripheral blood blasts, n (%) 
0% 7 (5.4)
 >0% 94 (72.3)
 Unknown 29 (22.3)
 Median (range), % 15 (0-90)
Bone marrow blasts, n (%) 
 20%-30% 36 (27.7)
 >30% (off-label use) 80 (61.5)
 Unknown 14 (10.8)
Median (range), % 49.5 (20-97)
WBC count (109/L), n (%) 
 ≤10x109/L 77 (59.2)
 >10x109/L 53 (40.8)
 Median (range), % 4.9 (0.7-146)
ANC (109/L), median (range) 1.1 (0.05-142.7)
Hb (g/L), median (range) 8.7 (4.2-14)
Platelet count (109/L), median (range) 57 (5-786)
LDH (IU/L) 
 <225  
 ≥225 27 (20.8)
 Unknown 98 (75.4)
Transfusion dependency (TD), n (%) 5 (3.8)
 No 
 Any type of TD  
 RBC-TD 18 (13.8)
 PLT-TD 112 (86.2)
 RBC-TD + PLT-TD 40 (30.7)
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were documented in 13.1% (n=17), 6.2% (n=8), and 16.9% 
(n=22) of the cases, respectively (Table 2). Any HI according to 
IWG criteria was documented in 37.7% (n=49) of the patients; 
neutrophil, erythroid, and platelet responses were observed in 
18.5% (n=24), 3.8% (n=5), and 15.4% (n=20) of the patients, 
respectively (Table 2). HI was also documented in 27.1% (n=19) 
of 70 patients who were unresponsive to treatment.
Median overall survival (OS) was 12.3 [95% confidence interval 
(CI): 10.1-14.6] months as of the first diagnosis of AML. Disease-
free survival (DFS) and event-free survival (EFS) were 16.2 (95% 
CI: 6.7-25.7) and 8.3 (95% CI: 6.1-10.6) months, respectively. 
Median OS was 18 (95% CI: 10.6-25.4) months for responders 
(defined as CR/CRi/PR) and 12 (95% CI: 9.2-14.8) months for 
nonresponders (p=0.005). In addition, median OS was 14 (95% 
CI: 4.1-23.9) months in patients unresponsive to treatment 
(without CR/CRi/PR) but with any HI (n=19), and was 10 (95% 
CI: 4.1-15.9) months in patients unresponsive to treatment and 
also without any HI (n=51) (p=0.068). Median OS of the patients 
who received AZA as a rescue after intensive chemotherapy was 
24 (95% CI: 13.3-34.7) months as of the first diagnosis of AML. 
In univariate analysis the following parameters had a significant 
effect on both treatment response and OS: ECOG-PS score, 
number of AZA cycles, and any HI. However, sex, age, absolute 
number of comorbidities, presence of peripheral blasts, AML 
type, leukocyte count at the time of diagnosis, treatment 
prior to AZA, and BM blast count had no significant impact 
on treatment response and OS (Table 3). Since the number of 
patients with good (n=1) and poor-risk cytogenetics (n=7) was 
low, the effect of cytogenetics on response to treatment and 
OS was not evaluated. Similarly, since the number of patients 
receiving AZA at 100 mg/m2 was low (n=24), the impact of 
altered dosing schedules of AZA was not evaluated.
In multivariate analysis, all variables with p<0.05 in univariate 
analysis were included, and it was found that increasing number 
of AZA cycles (≥5) was associated with a better response rate 
and ECOG-PS score of ≥2 was a significant predictor of shorter 
OS (Table 4). 
Toxicity and Adverse Events
A total of 351 adverse events were documented. CTCAE grade 3-4 
neutropenia, thrombocytopenia, and anemia were documented 
in 34.6%, 40.8%, and 39.2% of patients, respectively. Febrile 
neutropenia was documented in 60.8% of the patients. Other 
nonhematological toxicities were usually mild, the most 
common adverse events being mucositis, diarrhea, injection site 
pain, and nausea.
Discussion
Incidence of AML increases with age and most patients are 
deemed unsuitable for intensive treatment options. Outcomes 
Table 1. Continuation
MRC cytogenetic risk, n (%)
Not evaluable 14 (10.7)
Good 58 (44.6)
Intermediate 56 (43.1)
High 1 (0.8)
Comorbidities, n (%) 66 (50.8)
Number of comorbidities, n (%) 7 (5.4)
 <3 86 (66.2)
 ≥3  77 (89.5)
ECOG-PS score, n (%)
 ECOG <2  9 (10.5)
 ECOG ≥2  52 (40)
 Unknown 71 (54.6)
Treatment prior to azacitidine, n (%) 7 (5.4)
 None 71 (54.6)
Reason for treatment, n (%)
 First-line treatment 103 (79.2)
 No CR to/early relapse after intensive    
 chemotherapy 18 (13.8)
 No CR to other prior treatments 9 (6.9)
t-AML: Treatment-related acute myeloid leukemia, AML-RCA: acute myeloid leukemia 
with recurrent cytogenetic abnormalities, AML-MRF: acute myeloid leukemia with 
MDS-related features, AML-NOS: acute myeloid leukemia not otherwise specified, 
WBC: white blood cell, ANC: absolute neutrophil count, Hb: hemoglobin, LDH: lactate 
dehydrogenase, RBC: red blood cell, PLT: platelet, MRC: myelodysplastic syndrome-
related cytogenetics, ECOG: Eastern Cooperative Oncology Group, G-CSF: granulocyte-
colony stimulating factor, CR: complete remission.
Table 2. Response to azacitidine according to International 
Working Group criteria. 
Response n (%)
No response 70 (53.8)
 Overall response1 47 (36.2)
 CR 17 (13.1)
 CRi 8 (6.2)
 PR 22 (16.9)
 Not evaluable 13 (10)
 HI  n (%)
 No HI 81 (62.3)
 Any HI 49 (37.7)
 Neutrophil response 24 (18.5)
 Erythroid response 5 (3.8)
Platelet response 20 (15.4) 
1Overall response includes CR, CRi, and PR.
CR: Complete response, CRi: complete response with incomplete recovery, PR: partial 
response, HI: hematologic improvement.
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following conventional chemotherapeutic approaches are poor. 
AZA is a hypomethylating agent, and owing to its acceptable 
tolerability profiles and emerging evidence of clinical efficacy, 
it may provide an exciting approach to the treatment of elderly 
patients with AML. It is licensed for patients with 20%-30% 
blasts and it confers a survival benefit in these patients [14]; 
studies suggest 10%-20% CR rates with AZA [14,19,20,21] and 
these patients have OS rates equivalent or superior to other 
conventional treatments [14,19,21]. However, data on AZA 
activity in AML patients with BM blast counts of >30% are 
limited and the drug can be used off-label in these patients, 
although several analyses have also suggested that AZA is active 
and well tolerated in patients with >30% BM blasts as well 
[11,12,15,20]. 
Table 3. Univariate analysis for response and overall survival. 
  Overall response rate, % p-value
Median overall survival,
months, and 95% CI
p-value
Sex,
Female/Male
44.4/36.5 0.383
12.3/13.3
10.3-14.3/9.1-17.6
0.303
Age,
60-69/70-79/≥80 years
44.7/37.9/38.1 0.783
19/12.3/15
3.9-34.1/10.2-14.5/1.2-28.9
0.057
Absolute number of
comorbidities, <3/≥3
33.8/55.6 0.273
13/9
10.2-15.8/1.6-16.4
0.662
Peripheral blasts,
0%/>0%
42.9/36.4 0.706
12.3/12.3
6.2-12.3/10.1-14.5
0.379
BM blast count,
20%-30%/>30%
41.7/39.1 0.801
13/12.3
7.8-18.2/9.6-15.1
0.929
AML type,
t-AML/AML-RCA/AML-MRF/AML-NOS
50.0/43.2/57.1/35.0 0.592
7/11.3/6/14.1
4.4-9.6/9.2-13.4/3.5-12.9/11.9-16.2
0.091
Treatment prior to AZA,
No/Yes
47.6/30.2 0.056
12.3/13.2
9.1-15.6/9.9-16.4
0.158
Leukocyte count at diagnosis, ≤10x109/
L/>10x109/L 40.3/40.0 0.976
14/10.5
8.9-19.1/7.8-13.1
0.225
LDH,
≥225/<225 IU/L
41.9/38.5 0.758
11/19
8.6-13.4/12.1-25.9
0.018
ECOG,
≥2/<2
29.7/53.2 0.012
10/14.1
8.1-11.9/7.8-20.3
0.034
Number of AZA cycles,
≥5/<5
61.9/28 0.001
14.1/9
8.5-19.6/4.0-14.0
0.011
Transfusion dependency,
Yes/No
36.3/66.7 0.025
12.3/20
9.8-14.8/4.2-35.9
0.077
Any HI,
Yes/No
59.6/27.1 0.001
18/10
10.0-26.0/5.1-14.9
0.002
CI: Confidence interval, BM: bone marrow, t-AML: treatment-related acute myeloid leukemia, AML-RCA: acute myeloid leukemia with recurrent cytogenetic abnormalities, AML-MRF: 
acute myeloid leukemia with MDS-related features, AML-NOS: acute myeloid leukemia not otherwise specified, LDH: lactate dehydrogenase, ECOG: Eastern Cooperative Oncology 
Group, AZA: azacitidine, HI: hematologic improvement.
Table 4. Multivariate analysis for response and overall survival. 
  Response Overall survival
  OR (95% CI) p-value HR (95% CI) p-value
LDH, ≥225/<225 IU/L 0.715 (0.248-2.058) 0.533 1.862 (0.977-3.549) 0.059
ECOG, ≥2/<2 2.360 (0.969-5.748) 0.059 1.677 (1.020-2.758) 0.042
Number of AZA cycles, ≥5/<5 0.312 (0.123-0.793) 0.014 0.576 (0.332-1.001) 0.050
Transfusion dependency, yes/no 3.165 (0.790-12.683) 0.104 1.509 (0.650-3.505) 0.339
Any HI, yes/no 0.311 (0.125-0.776) 0.012 0.621 (0.359-1.077) 0.090
OR: Odds ratio, CI: confidence interval, HR: hazard ratio, LDH: lactate dehydrogenase, ECOG: Eastern Cooperative Oncology Group, AZA: azacitidine, HI: hematologic improvement.
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In the current study, we retrospectively analyzed the efficacy and 
toxicity of AZA in 130 patients with AML who were ≥60 years 
of age, and this cohort also included 80 patients (61.5% of the 
cases) with >30% BM blasts. We found a CR rate similar to the 
CR rates of recent studies [14,19,20,21], which was documented 
in 13.1% of our patient cohort. Median OS was 12.3 months 
and OS was longer in responders compared to nonresponders. 
We also showed that AZA was effective in the group with >30% 
BM blasts and that BM blast count of 20%-30% versus >30% 
has no significant impact on response rate or OS. In addition, 
although the response rate and OS were somewhat poor 
with the presence of peripheral blasts, these results were not 
statistically significant. In a study conducted by van der Helm 
et al. it was shown that BM blast percentage had no impact 
on OS as well [22]. In a recent phase 3 study of AZA versus 
conventional care regimens in newly diagnosed AML patients 
of ≥65 years with >30% BM blasts, Dombret et al. confirmed 
the clinical observation that AZA can have meaningful clinical 
activity (e.g., transfusion independency) and improve survival, 
even though no CR is achieved [23]. Thus, we recommend that 
AML patients with >30% BM blasts should not be precluded 
from treatment with AZA and the presence of peripheral blasts 
should not be a reason for therapy cessation. 
HI was found to be a predictor of prolonged survival; significantly 
longer OS was observed in patients achieving any kind of HI 
compared to patients without any HI (p=0.002), and similar 
results have been shown in recent AML patient cohorts [15,20]. 
However, interestingly, we also found that in the unresponsive 
(without CR/CRi/PR) patient group, OS was significantly longer 
for patients who achieved HI compared to those without any HI 
(p=0.068). In other words, although this was not a statistically 
significant result, HI without CR/CRi or PR was also associated 
with a better OS. If commonly used AML response criteria were 
to be applied [17], patients who experience HI without CR, CRi, 
or PR would be called nonresponders and treatment with AZA 
would be discontinued. With these results, we can conclude that, 
since cytopenias are the cause of mortality in the majority of 
patients with AML, the goal of therapy with AZA should not just 
be CR or PR, and therapy should be continued in patients with 
any HI although there is not any simultaneous BM response. 
Another result of our study was that, as the number of AZA 
courses increased, response rate and OS increased. This is not 
a surprise, because the epigenetic therapeutic effects of AZA 
are dependent on the S-phase of the cell cycle and each cycle 
of therapy can only affect the fraction of the malignant clone 
that enters the S-phase. Thus, the best responses can occur after 
as many as 12 cycles of therapy, with a median of 3-3.5 cycles 
[24]. Therefore, the treatment should not be interrupted in the 
early stages of therapy and it should be continued as long as 
the response is durable and/or until overt clinical progression 
occurs.
We confirm the results of previous studies [15,20,25] that WHO-
AML type, treatment prior to AZA, sex, and age had no significant 
effect on OS. Not the age but rather the absolute number of 
comorbidities may adversely affect OS. In our study, a cut-off 
of <3/≥3 comorbidities was analyzed and there was a trend 
for reduced OS for patients with ≥3 comorbidities, which was, 
however, not statistically significant (p=0.662). Similarly, LDH of 
≥225 IU/L was associated with reduced OS (p=0.018), but it had 
no impact on treatment response (p=0.758). Importantly, ECOG-
PS of ≥2 was found to be the only baseline factor affecting OS in 
both univariate and multivariate analysis. Recently, an Austrian 
group reported that the absolute number of comorbidities and 
LDH of ≥225 IU/L were independent adverse predictors of OS in 
their larger cohort (n=302) [15] and borderline significant in 
their previously published smaller cohort (n=155) [20]. As we 
found in our study, ECOG-PS of ≥2 was an independent adverse 
predictor of OS in both of the Austrian studies [15,20], and in 
a French study as well [25]. In our opinion, older age, WHO-
AML type, prior treatments, and LDH level should not lead to 
a decision to withhold treatment of AZA in favor of BSC if the 
patient has an ECOG-PS score of <2.
Elevated leukocyte count had no impact on OS in our study, but 
conflicting results exist in the literature. Both aforementioned 
Austrian publications showed that leukocyte count of neither 
>10x109/L nor >15x109/L significantly affected OS [15,20], but 
the French publication showed a significant effect of leukocyte 
count of >15x109/L on OS [25]. We think that AML patients with 
high leukocyte counts should not be precluded from treatment 
with AZA, and cytoreduction with hydroxyurea or low-dose 
cytarabine may be an appropriate approach in such patients. 
As expected, transfusion dependence prior to AZA was 
associated with reduced OS in our study in univariate analysis, 
which was, however, not statistically significant (p=0.077). 
Transfusion dependence was not a predictor of reduced OS in 
the multivariate analysis of the Austrian studies, as well [15,20]. 
The most commonly observed toxicity was febrile neutropenia, 
at a rate higher than seen in the literature [12,13,15]. Other 
nonhematological toxicities were mild. However, due to the 
retrospective nature of this analysis, toxicities in general were 
probably underestimated. 
Certainly, our study has several shortcomings, since it was a 
retrospective study, the patient population was heterogeneous, 
and the effect of cytogenetics on response to treatment was 
not evaluated. 
In conclusion, AZA is effective and well tolerated in elderly 
comorbid AML patients with fewer required erythrocyte and 
platelet transfusions, irrespective of BM blast count. HI should 
be considered a sufficient response to continue treatment with 
AZA and treatment should not be interrupted since OS and 
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response to treatment increase with increasing numbers of AZA 
cycles.
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